Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM et al (2020) (2020) European Association of urology guidelines on upper tract urothelial carcinoma: 2020 update. Eur Urol. https://doi.org/10.1016/j.eururo.2020.05.042

Article  PubMed  PubMed Central  Google Scholar 

Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM, Psutka SP, Raman JD, Smith AB, Smith L (2023) Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline. J Urol 209(6):1071–1081. https://doi.org/10.1097/JU.0000000000003480. (Epub 2023 Apr 25 PMID: 37096584)

Article  PubMed  Google Scholar 

Grasso M, Fishman AI, Cohen J, Alexander B (2012) Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int 110(11):1618–1626. https://doi.org/10.1111/j.1464-410X.2012.11066.x. (Epub 2012 Mar 28 PMID: 22458598)

Article  PubMed  Google Scholar 

Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Rouprêt M (2016) Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 70(6):1052–1068. https://doi.org/10.1016/j.eururo.2016.07.014. (Epub 2016 Jul 28 PMID: 27477528)

Article  PubMed  Google Scholar 

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2015 Dec;68(6):970–7. doi: https://doi.org/10.1016/j.eururo.2015.07.039. Epub 2015 Aug 14. PMID: 26278805; PMCID: PMC4675454.

Grahn A, Eisfeldt J, Malm C, Foroughi Asl H, Jaremko G, Tham E, Brehmer M (2022) Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma. BJU Int 130(1):92–101. https://doi.org/10.1111/bju.15566. (Epub 2021 Aug 29 PMID: 34375486)

Article  CAS  PubMed  Google Scholar 

Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y, Ochi Y, Shiozawa Y, Aoki K, Yoshida K, Kataoka K, Nakagawa MM, Nannya Y, Makishima H, Miyakawa J, Kawai T, Morikawa T, Shiraishi Y, Chiba K, Tanaka H, Nagae G, Sanada M, Sugihara E, Sato TA, Nakagawa T, Fukayama M, Ushiku T, Aburatani H, Miyano S, Coleman JA, Homma Y, Solit DB, Kume H, Ogawa S (2021) Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 39(6):793-809.e8. https://doi.org/10.1016/j.ccell.2021.05.008.PMID:34129823;PMCID:PMC9110171

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vollmer T, Schlickeiser S, Amini L, Schulenberg S, Wendering DJ, Banday V, Jurisch A, Noster R, Kunkel D, Brindle NR, Savidis I, Akyüz L, Hecht J, Stervbo U, Roch T, Babel N, Reinke P, Winqvist O, Sherif A, Volk HD, Schmueck-Henneresse M. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Sci Transl Med. 2021 Jan 13;13(576):eabb3735. doi: https://doi.org/10.1126/scitranslmed.abb3735. PMID: 33441425.

Hiltbrunner S, Mints M, Eldh M, Rosenblatt R, Holmström B, Alamdari F, Johansson M, Veerman RE, Winqvist O, Sherif A, Gabrielsson S (2020) Urinary exosomes from bladder cancer patients show a residual cancer phenotype despite complete pathological downstaging. Sci Rep 10(1):5960. https://doi.org/10.1038/s41598-020-62753-x.PMID:32249794;PMCID:PMC7136268

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka N, Kaczynska D, Kanatani S, Sahlgren C, Mitura P, Stepulak A, Miyakawa A, Wiklund P, Uhlén P. Mapping of the three-dimensional lymphatic microvasculature in bladder tumours using light-sheet microscopy. Br J Cancer. 2018 Apr;118(7):995–999. doi: https://doi.org/10.1038/s41416-018-0016-y. Epub 2018 Mar 8. PMID: 29515257; PMCID: PMC5931093.

Sydén F, Baard J, Bultitude M et al (2023) Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up—where are we today? World J Urol. https://doi.org/10.1007/s00345-023-04530-9

Article  PubMed  Google Scholar 

Grahn A, Coleman JA, Eriksson Y et al (2023) Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods—What’s around the corner? World J Urol. https://doi.org/10.1007/s00345-023-04597-4

Article  PubMed  Google Scholar 

Calleris G, Rouprêt M, Seisen T et al (2023) Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756). World J Urol. https://doi.org/10.1007/s00345-023-04596-5

Mu N, Jylhä C, Axelsson T et al (2023) Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC. World J Urol. https://doi.org/10.1007/s00345-023-04583-w

Article  PubMed  Google Scholar 

Figaroa, O.J.A., Hendriks, N., Kamphuis, G.M. et al. Positioning the role of urine cytology within the diagnostic pathway for UTUC: supportive but inconclusive. World J Urol (2023). https://doi.org/10.1007/s00345-023-04689-1